About this trial
This study aimed to evaluate the effects of a Low-FODMAP diet on intestinal permeability, symptom severity, and quality of life in patients with Irritable Bowel Syndrome (IBS). Twenty-four patients diagnosed with IBS according to the Rome IV criteria were randomized to either a Low-FODMAP diet or a traditional diet for four weeks. Stool zonulin family peptides (ZFP), IBS Symptom Severity Score (IBS-SSS), and IBS Quality of Life (IBS-QOL) questionnaires were recorded at baseline and after the dietary intervention. In the Low-FODMAP group, FODMAP-containing foods were gradually reintroduced under dietitian supervision, and assessments were repeated at week 16 to evaluate long-term effects.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
IBS-specific treatment within the last 1 month
Trial design
Parallel
Treatments tested in this trial
low fodmap diet
Other interventionexperimental group consume low fodmap diet
dietary intervention
Other interventiondietary interventionlow fodmap diet
Treatment groups
Trial outcomes
Primary outcomes
change zonulin levels in IBS patient
We aim to investigate that lox fodmap diet has decreased stool zonulin level and improve leaky gut or not
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Istanbul Medipol University Hospital
Lead sponsor
Medipol University
Collaborator
This trial is not recruiting at the moment. You can still explore other options: